Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares, rose in value on Friday, 03/03/23, with the stock price up by 5.51% to the previous day’s close as strong demand from buyers drove the stock to $2.49.
Actively observing the price movement in the last trading, the stock closed the session at $2.36, falling within a range of $2.35 and $5.08. The value of beta (5-year monthly) was 1.45. Referring to stock’s 52-week performance, its high was $43.00, and the low was $2.26. On the whole, CYTO has fluctuated by -13.84% over the past month.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could “deliver huge returns.” Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
With the market capitalization of Altamira Therapeutics Ltd. currently standing at about $2.91 million, investors are eagerly awaiting this quarter’s results, scheduled for Nov 30, 2022.
Analysts have estimated the company’s revenue for the quarter at $59.1 million, with a low estimate of $59.1 million and a high estimate of $59.1 million.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CYTO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 1 recommend it as a Buy and 0 called the CYTO stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CYTO currently trading nearly -5.54% and -34.06% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.57, while the 7-day volatility ratio is showing 30.63% which for the 30-day chart, stands at 12.36%. Furthermore, Altamira Therapeutics Ltd. (CYTO)’s beta value is 1.40, and its average true range (ATR) is 0.43. The company’s stock has been forecasted to trade at an average price of $286.10 over the course of the next 52 weeks, with a low of $286.10 and a high of $286.10. Based on these price targets, the low is -11389.96% off current price, whereas the price has to move -11389.96% to reach the yearly target high. Additionally, analysts’ median price of $286.10 is likely to be welcomed by investors because it represents a decrease of -11389.96% from the current levels.
Data on historical trading for Altamira Therapeutics Ltd. (NASDAQ:CYTO) indicates that the trading volumes over the past 10 days have averaged 14170.0 and over the past 3 months, they’ve averaged 41.43K. According to company’s latest data on outstanding shares, there are 1.17 million shares outstanding.
Nearly 7.10% of Altamira Therapeutics Ltd.’s shares belong to company insiders and institutional investors own 1.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8020.0 shares as on Jan 30, 2023, resulting in a short ratio of 0.1. According to the data, the short interest in Altamira Therapeutics Ltd. (CYTO) stood at 0.62% of shares outstanding as of Jan 30, 2023; the number of short shares registered in Dec 29, 2022 reached 37510.0. The stock has fallen by -48.66% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYTO stock heading into the next quarter.